Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
1501-1520 of 1,694 trials

Alcohol Dependence: CBD and Naltrexone Study

We are investigating whether adding Cannabidiol to Naltrexone helps reduce alcohol cravings in people with alcohol dependence. The study also looks at its effects on mood, anxiety, and overall quality of life.

Alcohol Dependence>2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemotePsychiatry

EGFR-Mutated Lung Cancer: ERIS Study

We are exploring the best sequence of EGFR-inhibitors for patients with EGFR-mutated lung cancer. The study also examines treatment effects, side effects, and quality of life.

EGFR-Mutated Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesOncology

Cancer Anorexia: ART27.13 Cannabinoid Study

We are testing a new synthetic cannabinoid to see if it helps patients with cancer gain weight and improve appetite. The study also looks at the safety and quality of life for participants.

Cancer Anorexia3-6 monthsSafety phase (I)Efficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementInternal MedicineOncology

Hidradenitis Suppurativa: IC0624 Treatment Study

We are testing a new medication, IC0624, for people with mild to moderate Hidradenitis Suppurativa. The study will help us understand its effects on symptoms, pain, and overall quality of life.

Hidradenitis Suppurativa≤3 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesDermatology

HER2-Positive Breast Cancer: New Treatment Without Chemotherapy

We are studying a combination of trastuzumab, pertuzumab, and tucatinib for patients with stage II-III HER2-positive breast cancer. The goal is to evaluate the safety and initial effectiveness of this chemotherapy-free approach.

HER2 Positive Breast Cancer1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Pancreatic Cancer: Napabucasin with Chemotherapy

We are studying how well Napabucasin works with chemotherapy for patients with metastatic pancreatic cancer after previous treatments have failed. The goal is to see if this combination improves survival and quality of life compared to standard care.

Metastatic Pancreatic CancerEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Prolonged Grief Disorder: PEX010 Treatment

We are testing a new treatment called PEX010 for people experiencing prolonged grief disorder. The study aims to see if it can significantly reduce grief symptoms and explore the effects of self-touch.

Prolonged Grief Disorder≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Non-Small Cell Lung Cancer: Drug Sequencing Study

We are investigating the best order to use two medications for patients with advanced non-small cell lung cancer that has specific mutations. This study aims to see which treatment sequence may improve outcomes for these patients.

Non-small Cell Lung Cancer (NSCLC)>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Dopamine Changes in Depression: Escitalopram vs. Bupropion

We are studying how rewards affect dopamine levels in the brain of people with major depressive disorder compared to healthy volunteers. This trial also looks at how two different antidepressants may influence these changes.

Major Depression>2 yearsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesPsychiatry

Heart Failure Treatment: Sacubitril/Valsartan vs. Ramipril

We are studying how two heart medications affect heart function in patients with ischemic heart failure. Our goal is to see which treatment better helps improve heart structure and performance.

Congestive Heart Failure1-2 yearsConfirmation phase (III)Standard MedicinesCardiologyInternal Medicine

Zinc Acexamate for Advanced Chronic Liver Disease

We are studying whether Zinc Acexamate can improve health outcomes for patients with advanced chronic liver disease. This trial compares its effects to a placebo to see if it reduces complications and improves survival.

Advanced Chronic Liver Disease>2 yearsConfirmation phase (III)Standard MedicinesHepatologyInternal Medicine

Primary Plasma Cell Leukemia: New Treatment with Bortezomib and Daratumumab

We are studying a combination of medications for people with primary plasma cell leukemia to see if it improves treatment outcomes and safety. This trial will help us understand how well this new approach works compared to current treatments.

Plasma Cell Leukemia>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesHematologyOncology

Atorvastatin for Patients with Chronic Myeloproliferative Neoplasms

We are studying whether atorvastatin can improve health markers in patients with specific blood disorders. This trial looks at its effects alongside standard treatments to see how it may help manage symptoms and disease progression.

Blood Cancer3-6 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesHematologyInternal Medicine

Polymyalgia Rheumatica: Hydrocortisone Supplement Study

We are investigating whether supplemental hydrocortisone helps improve quality of life for patients with polymyalgia rheumatica or giant cell arteritis experiencing adrenal insufficiency. The focus is on how it affects fatigue during stress.

Glucocorticoid Induced Adrenal Insufficiency6-12 monthsMonitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteEndocrinologyRheumatology

Multiple Sclerosis: CBD for Sleep Quality

We are investigating whether cannabidiol (CBD) can improve sleep quality in patients with multiple sclerosis. This study aims to help those struggling with sleep issues related to their condition.

Insomnia3-6 monthsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteInternal MedicineNeurology

Cirrhosis: Carvedilol for Preventing Digestive Bleeding

We are studying whether Carvedilol can help prevent digestive bleeding in patients with cirrhosis. The trial measures its effects on liver pressure and overall tolerance over three months.

Cirrhotic Portal Hypertension3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyInternal Medicine

Fertility Study: Metformin for Women Post-Thyroid Cancer

We are evaluating whether metformin can improve fertility in women treated with radioactive iodine for thyroid cancer. The study will look at hormone levels and ovarian health to see how effective the treatment is.

Papillary Thyroid Carcinoma1-2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesGynecology and ObstetricsOncology

Lung Cancer Treatment: Divarasib and Pembrolizumab

We are studying a new treatment combination for patients with advanced non-small cell lung cancer that has a specific genetic mutation. The goal is to see if this new approach improves survival and quality of life compared to standard treatments.

Advanced Non-Squamous Non-Small Cell Lung Cancer1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Siponimod for Progressive Multiple Sclerosis

We are studying how siponimod affects brain lesions and nerve damage in patients with secondary progressive MS. The trial also looks at its impact on cognitive health and long-term safety.

Progressive Multiple Sclerosis>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesNeurology

Idiopathic Membranous Nephropathy: AP1189 Study

We are exploring whether the medication AP1189 can improve kidney function and reduce protein in urine for patients with idiopathic membranous nephropathy. This study involves patients already receiving ACE inhibitors or angiotensin II receptor blockers.

Membranous Nephropathy1-2 yearsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementInternal MedicineNephrology